LAGUNA HILLS, Calif. , Oct. 2, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results of a cutting-edge study in Clinical Breast Cancer .
The study, marks a significant advancement in personalized treatment for DCIS patients. The study evaluated HER2-positive patients treated with breast conserving surgery (BCS) plus radiation therapy (RT) to determine if the DCISionRT test could identify those patients with elevated residual risk remaining after treatment. The study showed that patients with the DCISionRT Residual Risk subtype had significantly higher in-breast recurrence (IBR) rates compared to those without the Residual Risk subtype (16.
2% vs 1.6%, p=.01).
Dr. Frank Vicini , a leading investigator on this study said, "The identification of this residual risk subtype opens new avenues for tailored treatments. It particularly highlights the possible benefit of Trastuzumab in this subset of patients, as we've been investigating in the NSABP-B43 trial.
These results could significantly impact how we approach treatment for HER2-positive DCIS patients moving forward." "We're very encouraged by the latest publication," says Dan Forche , President and CEO of PreludeDx. "This study represents a significant opportunity to bring companion diagnostics and targeted treatment into the area of DCIS, marking a pivotal step in PreludeDx's commitment to advancing personalized medicine in breast cancer .
